So excited to share that my IIT - Gilteritinib for the Treatment of ALK NSCLC - is finally open to accrual!
clinicaltrials.gov/study/NCT06225…

Grateful to ALK Positive and LUNGevity Foundation for their support. Here's to making a difference for patients with ALK+ NSCLC. U-M Rogel Cancer Center

🚀Excited to kick off ⁦OBR Oncology⁩ ‘Leading Thoughts in Lung Cancer’ Series with #lcsm friends Maya K. Khalil, MD Sandip Patel MD!

Ep.1: First-Line Treatment of EGFR+ mNSCLC

Thanks to our predecessors, H. Jack West, MD Charu Aggarwal, MD, MPH, FASCO Devika Das, MD, MSHQS! obroncology.com/leading-though…

👏🏻Carolyn Presley, MD MHS recognized for presenting the 2023 Jimmie Holland Lecture at the Alliance for Clinical Trials in Oncology

A huge congrats to Daniel Stover, MD, FASCO who was awarded the Ohio State Medical Oncology FY24Q3 Highest Clinical Performance award The James for optimal clinic utilization, high patient sat scores and quick closing rate! #DoubleThreat Physician-Scientist who is rocking clinic and lab #bcsm 🎉

Phase III ALINA trial of adjuvant alectinib for resected stage Ib-IIIA (AJCC v7) #ALK NSCLC now NEJM. Compared 2y of alectinib to chemotherapy. Alectinib improved DFS (HR 0.24) with 2y DFS rate 94% vs 63%! CNS DFS 0.22, OS pending. Standard of care IMO.

nejm.org/doi/full/10.10…

Insights into the latest ASCO NSCLC Living Guidelines available JCO Oncology Practice from Dr. Dwight Owen et al, addressing some common questions and providing helpful decision trees for personalizing systemic therapy for patients with NSCLC.

ascopubs.org/doi/10.1200/OP…

Dr. Adam Khorasanchi, one of our #medonc hospitalists, presenting on OS impact for #NSCLC patients with irAE and non-irAE hospital admissions during first-line pembrolizumab treatment at #NCCN24 National Comprehensive Cancer Network (NCCN)

📝New publication from Dwight Owen & colleagues: Therapy for Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights ASCO JCO Oncology Practice
doi.org/10.1200/OP.24.…

Important letter to the editor Annals of Oncology on immune related adverse events. Do we know what is truly immune related? Need to capture all-cause AEs for discovery purposes. And we desperately need harmonization of CTCAE to align terms. ESMO - Eur. Oncology

annalsofoncology.org/article/S0923-…

Congratulations Dr. Borghaei Hossein Borghaei, DO and Dr. Chiang Anne Chiang for completion of #NCTN ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network Trial EA5163/S1709: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in #NSCLC . More: buff.ly/3ICG2Hw

Man it really bothers me when people label certain specialty residency programs as “easy.” All it does is invalidate any mental/physical challenges trainees may have, and it’s just flat out wrong.

📝New publication from Dwight Owen & colleagues: Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer #nsclc Journal of the @NCCN The James
doi.org/10.6004/jnccn.…

In a cohort at average risk for colorectal cancer, a cell-free DNA blood-based test had 83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia, and 13% sensitivity for advanced precancerous lesions. Full ECLIPSE study results: nej.md/3v0J319

Out now in JTO & JTO CRR excellent work from Drs. valter torri Hines, Cameron & Marina Garassino over 2500 pts in neoadjuvant & perioperative trials to date, pCR appears predictive of EFS, early days for OS. #lcsm jto.org/article/S1556-…

Dr. Dwight Owen Dwight Owen from Ohio State Medical Oncology The James highlights the unique variables for the management of #immunotherapy and need for adequate #NGS testing in #NSCLC at the #IULungSymposium

#LCSM IU Simon Comprehensive Cancer Center #EndLungCancerNow Greg Durm

Highlight of the #IULungSymposium is getting to hear Dr. Larry Einhorn discuss the field. Poses critical questions for the field. One of the great speakers in thoracic oncology. #LCSM

We summarized it and created a flow chart!

Amazing team at the ASCO NSCLC guidelines led by Dwight Owen Jyoti Patel Erin Schenk, MD, PhD Joshua Reuss and many more!

Registered for Pelotonia 2024! Can’t believe it’s my 5th (!!) year participating with a goal to raise $1500 for cancer research. I better start those training rides in preparation for the 50 mile journey #OneGoal #BeLegendary pelotonia.org/profile/MG0328

Congrats to Dr. Greg Otterson on retirement! But bittersweet for us at Ohio State Medical Oncology - This place wouldn't be 'this place' without all he has done. Thanks GAO for your mentorship, guidance, and friendship, and enjoy this next adventure! The James Pelotonia

We’ve issued a living guideline update on therapy for stage IV #NSCLC without driver alterations: brnw.ch/21wHq2q
#lungcancer #lcsm